Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arbutus Biopharma Corp ABUS

Healthcare Biotechnology
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran... see more

Recent & Breaking News (NDAQ:ABUS)

Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer

GlobeNewswire June 7, 2018

Research Report Identifies Diodes, Arbutus Biopharma, Radware, Immutep, Amarin, and SPS Commerce with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire June 6, 2018

Arbutus Announces Corporate Update and First Quarter 2018 Financial Results

GlobeNewswire May 3, 2018

Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results

GlobeNewswire April 30, 2018

Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018

GlobeNewswire April 12, 2018

Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases

GlobeNewswire April 11, 2018

15 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  October 3, 2017

Arbutus to Present HBV Data at 2017 AASLD Liver Meeting

GlobeNewswire October 3, 2017

Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences

GlobeNewswire October 2, 2017

Arbutus to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 25, 2017

Arbutus Announces Topline Results for ARB-1467 Phase II Cohort 4

GlobeNewswire September 25, 2017

Arbutus Presents HBV Data at Upcoming Scientific Conferences

GlobeNewswire September 22, 2017

Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program

GlobeNewswire September 20, 2017

Arbutus to Host Live Webinar on Developments of LNP Delivery for mRNA-based Therapeutics

GlobeNewswire September 7, 2017

Arbutus to Present at 2017 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 14, 2017

Arbutus Announces Corporate Update and Second Quarter 2017 Financial Results

GlobeNewswire August 3, 2017

Investor Network: Arbutus Biopharma Corporation to Host Earnings Call

Accesswire August 3, 2017

Arbutus Announces Conference Call to Provide a Corporate Update and Second Quarter 2017 Financial Results

GlobeNewswire August 1, 2017

Arbutus Announces Conclusion of LNP License Agreement with Alexion

GlobeNewswire July 27, 2017

Arbutus to Participate in Upcoming Investor Conferences

GlobeNewswire June 2, 2017